Abstract

Background:Motor Neuron Disease (MND) is a progressive neurodegenerative disorder leading to respiratory muscle weakness with dyspnoea, morning headaches, orthopnoea, poor concentration, unrefreshing sleep, fatigue and daytime somnolence. Respiratory failure is the primary cause of death in those with MND.Methods:Although guidelines suggest the use of non-invasive ventilation (NIV) in MND, there lacks clear guidance as to when is the optimal time to initiate NIV and which markers of respiratory muscle decline are the best predictors of prognosis. There have been a number of studies that have found a significant survival advantage to the use of NIV in MND. Similarly, in quality-of-life questionnaires, those treated with NIV tend to perform better and maintain a better quality of life for longer. Furthermore, studies also suggest that improved compliance and greater tolerance of NIV confer a survival advantage.Results and Discussion:Forced Vital Capacity (FVC) has traditionally been the main pulmonary function test to determine the respiratory function in those with MND; however, FVC may not be entirely reflective of early respiratory muscle dysfunction. Evidence suggests that sniff nasal inspiratory pressure and maximum mouth inspiratory pressure may be better indicators of early respiratory muscle decline. These measures have been shown to be easier to perform later in the disease, in patients with bulbar onset disease, and may indeed be better prognostic indicators.Conclusion:Despite ongoing research, there remains a paucity of randomised controlled data in this area. This review aims to summarise the evidence to date on these topics.

Highlights

  • Motor Neuron Disease (MND) is a neurodegenerative disorder that leads to progressive muscle weakness and respiratory compromise as a result of the loss of motor neurons in the brain, brainstem, and spinal cord [1 - 3]

  • The only approved drug in MND is riluzole, which works by slowing disease progression and has been shown to prolong survival by 2-3 months [6]. This current review aims to summarise the evidence to date regarding the use of Non-Invasive Ventilation (NIV) in MND and establish the effects it has on the quality of life and survival

  • non-invasive ventilation (NIV) has a role in the treatment of patients with MND as it has benefits when it comes to survival and improvements in quality of life

Read more

Summary

Introduction

Motor Neuron Disease (MND) is a neurodegenerative disorder that leads to progressive muscle weakness and respiratory compromise as a result of the loss of motor neurons in the brain, brainstem, and spinal cord [1 - 3]. Survival is approximately 3-5 years, with the most common cause of death being respiratory failure [1 - 4]. The estimated incidence of MND in the UK is 2.76 per 100,000 [5]. There is no cure for MND, but there have been numerous advances which. 54 The Open Respiratory Medicine Journal, 2020, Volume 14 Walsh and Murphy. Motor Neuron Disease (MND) is a progressive neurodegenerative disorder leading to respiratory muscle weakness with dyspnoea, morning headaches, orthopnoea, poor concentration, unrefreshing sleep, fatigue and daytime somnolence. Respiratory failure is the primary cause of death in those with MND

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call